Trial Profile
Efficacy and Safety of Sugammadex (2mg/kg) to Shorten Time-to-extubation Among Postoperative ICU Patients Following AVR, CABG Surgery, or AVR/CABG Surgery- a Prospective Randomized Placebo-controlled Trial.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 09 Oct 2020 Status changed from recruiting to completed.
- 12 Aug 2020 Planned End Date changed from 30 Dec 2020 to 1 Mar 2021.
- 12 Aug 2020 Planned primary completion date changed from 30 Jun 2020 to 1 Dec 2020.